GAL3ST1 and Alzheimer disease: To accomplish this goal, we established an inducible myelinating cell-specific CST KO mouse model and halted sulfatide biosynthesis after myelin development/maturation, mimicking the type of sulfatide losses that occur in AD brains, and administered tamoxifen at 3–4 mo of age, when their myelin is largely formed and they already contain abundant matured oligodendrocytes [58].